RIGL Maintained at Buy by H.C. Wainwright, May 2026

H.C. Wainwright maintained its Buy rating on Rigel Pharmaceuticals (RIGL) on May 12, 2026, affirming confidence in the biotech firm’s strategic direction. The analyst firm’s decision comes as Pfizer hands off its Veppanu asset to Rigel, a move the firm says “makes strategic sense.” RIGL trades at $29.37, up 12.1% in one day, reflecting strong market momentum. With a market cap of $543.4 million, Rigel continues to build its pipeline in hematologic disorders and rare immune diseases. The maintained rating signals analyst support for the company’s growth trajectory.

H.C. Wainwright’s Maintained Buy Rating on RIGL

Rating Action and Timing

H.C. Wainwright held its Buy rating on RIGL analyst rating following the Pfizer Veppanu transfer announcement. The analyst firm published its assessment on May 12, 2026, at 12:12 PM ET. This maintained stance reflects confidence in Rigel’s ability to absorb and commercialize the asset. The stock was trading at $28.85 when the rating was published, showing solid market reception to the news.

Strategic Rationale

The analyst firm believes Pfizer’s decision to hand off Veppanu to Rigel demonstrates strategic alignment with the biotech’s core competencies. H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’, positioning the smaller firm as a capable steward of the asset. This transfer strengthens Rigel’s portfolio in its focus areas. The maintained rating underscores analyst belief in management’s execution capabilities.

RIGL Stock Performance and Market Momentum

Recent Price Action

RIGL surged 12.1% to $29.37 on the analyst rating news and Veppanu announcement. The stock moved from a previous close of $26.20, gaining $3.17 in a single trading session. Volume spiked to 1.23 million shares, more than triple the average daily volume of 365,926 shares. This elevated activity signals strong investor interest in the company’s strategic pivot.

Technical Positioning

The stock trades within a 52-week range of $17.65 to $52.24, showing volatility typical of biotech firms. The 50-day moving average sits at $28.64, while the 200-day average is $34.38. RIGL’s current price reflects recovery momentum but remains below its year-high. The maintained Buy rating provides technical support for continued upside potential.

Rigel’s Pipeline and Strategic Assets

Core Product Portfolio

Rigel’s flagship asset is Tavalisse, an oral spleen tyrosine kinase inhibitor approved for chronic immune thrombocytopenia in adults. The company also develops Fostamatinib, currently in phase III trials for warm autoimmune hemolytic anemia and COVID-19 treatment. These programs target high-unmet-need indications in hematology and immunology. The Veppanu acquisition from Pfizer expands Rigel’s commercial reach and revenue potential.

Early-Stage Development

Rigel is advancing R289, an oral interleukin receptor associated kinase inhibitor in phase I trials for autoimmune and hematology-oncology diseases. The company also progresses R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that completed phase I testing. Strategic partnerships with AstraZeneca, Eli Lilly, and Daiichi Sankyo strengthen Rigel’s development capabilities and reduce capital requirements.

Meyka AI Grade and Financial Metrics

Meyka Stock Grade Assessment

Meyka AI rates RIGL with a grade of B+, reflecting solid fundamentals and growth potential. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 79.58 out of 100 suggests the stock is positioned favorably relative to peers. These grades are not guaranteed and we are not financial advisors.

Key Financial Metrics

RIGL trades at a P/E ratio of 1.47, significantly below market averages, indicating potential undervaluation. The company maintains a current ratio of 2.62, showing strong liquidity and financial stability. Net profit margin stands at 121.5%, reflecting profitable operations. With 18.5 million shares outstanding and a market cap of $543.4 million, Rigel remains a small-cap biotech with significant growth runway.

Final Thoughts

H.C. Wainwright’s maintained Buy rating on RIGL reflects confidence in Rigel Pharmaceuticals’ strategic direction and asset acquisition from Pfizer. The 12.1% stock surge demonstrates strong market validation of the Veppanu handoff and the company’s ability to execute. With a B+ Meyka grade and attractive valuation metrics, RIGL presents a compelling profile for biotech investors. The maintained rating, combined with early-stage pipeline progress and strategic partnerships, positions Rigel for potential long-term value creation. Investors should monitor upcoming clinical trial data and commercial execution metrics closely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.